These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9695225)

  • 1. [Plasma hemostasis and biochemical indices in trimetazidine treatment of patients with chronic heart failure].
    Tereshchenko SN; Drozdov VN; Levchuk NN; Demidova IV
    Ter Arkh; 1998; 70(6):41-4. PubMed ID: 9695225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure].
    Song HM; Zhang J; Deng B; Luo M
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(25):1737-40. PubMed ID: 16253158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
    Skwarek M; Bilińska ZT; Mazurkiewicz Ł; Grzybowski J; Kruk M; Kurjata P; Piotrowski W; Ruzyłło W
    Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The angiotensin-converting enzyme inhibitor perindopril in the treatment of congestive heart failure].
    Tereshchenko SN; Drozdov VN; Demidova IV; Levchuk NN; Moiseev VS
    Ter Arkh; 1997; 69(7):53-6. PubMed ID: 9424761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
    Broncel M; Marczyk I; Kostka B; Michalska M; Sikora J; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):21-4. PubMed ID: 17477084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
    Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
    Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors].
    Spring A; Jołda-Mydłowska B; Kosmala W; Witkowska M
    Pol Merkur Lekarski; 1998 Jun; 4(24):315-8. PubMed ID: 9771014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
    Sasaki T; Kubo T; Komamura K; Nishikimi T
    J Cardiol; 1999 Jun; 33(6):317-25. PubMed ID: 10396705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
    Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study.
    Sanada S; Asanuma H; Koretsune Y; Watanabe K; Nanto S; Awata N; Hoki N; Fukunami M; Kitakaze M; Hori M
    Hypertens Res; 2007 Oct; 30(10):913-9. PubMed ID: 18049022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic alterations in patients with acute, unilateral vestibular paresis.
    Fattori B; Nacci A; Casani A; Cristofani R; Sagripanti A
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):401-7. PubMed ID: 11283497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.